Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Medivolve Inc MEDVF

Medivolve Inc. is a Canadian healthcare technology company. The Company and its subsidiaries, Medivolve Pharmacy Inc. (doing business as Marbella Pharmacy) and Kedy Ying Jao D.O., a Medical Corporation, operate a distributed network of two retail patient-care locations in California, United States. It has two business units: Medivolve Pharmacy Division (MPD) and Medivolve Clinic Services Division (MCSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine and psychiatry to patients in Southern California. MCSD provides licensed healthcare through a clinic in Brea, California, United States. MCSD is focused on developing a telehealth platform, which connects patients with physicians, and facilitates and manages the provision of virtual consultation, diagnosis, and treatment services in partnership with qualified health practitioners.


OTCPK:MEDVF - Post by User

Post by TOPDOGon Aug 04, 2020 9:57am
57 Views
Post# 31360367

Quetcap Enters new agreement to acquire 40% of Spectral Anal

Quetcap Enters new agreement to acquire 40% of Spectral AnalTORONTO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- QuestCap Inc. (“QuestCap” or the “Company”) (CSE:QSC; FRA:34C1) is excited to announce it has entered into an arms’ length agreement to acquire a 40% equity interest in Spectral Analytics, Inc. (“Spectral”).  As consideration for the acquisition of the 40% equity interest in Spectral, QuestCap shall issue to certain shareholders of Spectral 10 million QuestCap common shares and also make a conditional payment of US$470,000 to Spectral to fund certain clinical trials.  The payment of the US$470,000 is conditional on IRB approval including the submission by Spectral of a successful in vitro study to the US Food and Drug Administration (FDA) for human trials for a combination of two FDA approved drugs.  QuestCap shall also receive a warrant to acquire an additional 5% of Spectral for an exercise price of US$150,000 (included in the payment of US$470,000) exercisable following successful future human trial results as determined by QuestCap and as measured by the FDA.

read more here

https://www.globenewswire.com/news-release/2020/08/04/2072325/0/en/QuestCap-Announces-Agreement-to-Acquire-40-of-Spectral-Analytics.html
<< Previous
Bullboard Posts
Next >>